These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1512 related items for PubMed ID: 9537249

  • 1. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, Jensen PB.
    Cancer Res; 1998 Apr 01; 58(7):1460-8. PubMed ID: 9537249
    [Abstract] [Full Text] [Related]

  • 2. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I, Jensen LH, Jensen PB, Falck J, Rose A, Roerth M, Nitiss JL, Sehested M.
    Cancer Res; 1999 Jul 15; 59(14):3442-50. PubMed ID: 10416608
    [Abstract] [Full Text] [Related]

  • 3. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE, Cadena RS, Raimondi SC, Beck WT.
    Mol Pharmacol; 2000 Feb 15; 57(2):296-307. PubMed ID: 10648639
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
    Ishida R, Hamatake M, Wasserman RA, Nitiss JL, Wang JC, Andoh T.
    Cancer Res; 1995 Jun 01; 55(11):2299-303. PubMed ID: 7757979
    [Abstract] [Full Text] [Related]

  • 6. A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo.
    Grauslund M, Thougaard AV, Füchtbauer A, Hofland KF, Hjorth PH, Jensen PB, Sehested M, Füchtbauer EM, Jensen LH.
    Mol Pharmacol; 2007 Oct 01; 72(4):1003-14. PubMed ID: 17622580
    [Abstract] [Full Text] [Related]

  • 7. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
    Khélifa T, René B, Le Mée S, Lambert B, Saucier JM, Markovits J, Jacquemin-Sablon H, Jacquemin-Sablon A.
    Cancer Res; 1999 Oct 01; 59(19):4927-36. PubMed ID: 10519406
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells.
    Hasinoff BB, Abram ME, Chee GL, Huebner E, Byard EH, Barnabé N, Ferrans VJ, Yu ZX, Yalowich JC.
    J Pharmacol Exp Ther; 2000 Nov 01; 295(2):474-83. PubMed ID: 11046078
    [Abstract] [Full Text] [Related]

  • 12. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
    Sullivan DM, Latham MD, Ross WE.
    Cancer Res; 1987 Aug 01; 47(15):3973-9. PubMed ID: 3038304
    [Abstract] [Full Text] [Related]

  • 13. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H, Rodgers QE, Boege F, Raimondi SC, Beck WT.
    Cancer Res; 1996 Jun 01; 56(11):2573-83. PubMed ID: 8653700
    [Abstract] [Full Text] [Related]

  • 14. Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity.
    Hirota H, Gosky D, Berger NA, Chatterjee S.
    Int J Oncol; 2002 Feb 01; 20(2):311-8. PubMed ID: 11788894
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II.
    Sorensen TK, Grauslund M, Jensen PB, Sehested M, Jensen LH.
    Biochem Biophys Res Commun; 2005 Sep 02; 334(3):853-60. PubMed ID: 16053917
    [Abstract] [Full Text] [Related]

  • 17. A novel point mutation in the 3' flanking region of the DNA-binding domain of topoisomerase II alpha associated with acquired resistance to topoisomerase II active agents.
    Hashimoto S, Danks MK, Chatterjee S, Beck WT, Berger NA.
    Oncol Res; 1995 Sep 02; 7(1):21-9. PubMed ID: 7549041
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
    Ritke MK, Allan WP, Fattman C, Gunduz NN, Yalowich JC.
    Mol Pharmacol; 1994 Jul 02; 46(1):58-66. PubMed ID: 8058057
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 76.